Results
1 -
10 of
21Rye Carl S., Chessum Nicola E. A., Lamont Scott, Pike Kurt G., Faulder Paul, Demeritt Julie, Kemmitt Paul, Tucker Julie, Zani Lorenzo, Cheeseman Matthew D., Isaac Rosie, Goodwin Louise, Boros Joanna, Raynaud Florence, Hayes Angela, Henley Alan T., de Billy Emmanuel, Lynch Christopher J., Sharp Swee Y., te Poele Robert, Fee Lisa O’, Foote Kevin M., Green Stephen, Workman Paul, Jones Keith.
Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9, Med. Chem. Commun., 2016 Bagul chandrakant, Rao Garikapati Koteswara, Makani Venkata Krishna Kanth , Tamboli Jaki R , Bhadra Manika Pal, Kamal Ahmed.
Synthesis and biological evaluation of chalcone-linked pyrazolo[1,5-a]pyrimidines as potential anticancer agents, Med. Chem. Commun., 2017 Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review, Annals of Hematology Cell Cycle-Related Kinases, Cancer Therapeutic Targets Exploiting Cell Cycle Pathways in Cancer Therapy: New (and Old) Targets and Potential Strategies, Nuclear Signaling Pathways and Targeting Transcription in Cancer Resistance Mechanisms to Cyclin-Dependent Kinase Inhibitors, Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways Computational Screening of DrugBank DataBase for Novel Cell Cycle Inhibitors, Application of Computational Intelligence to Biology Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias, Cancer Chemotherapy and Pharmacology Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies, Cancer Chemotherapy and Pharmacology Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients, Cancer Chemotherapy and Pharmacology